Market Overview

3 Reasons Philip Morris Could Still Receive FDA Approval For Its 'Safer' Cigarette

3 Reasons Philip Morris Could Still Receive FDA Approval For Its 'Safer' Cigarette
Related PM
Analysts Weigh In On The FDA's Position On E-Cigarettes, Menthols
How The FDA May Be Overstepping Bounds With New E-Cigarette Policy
Top Holdings Of Dividend ETFs (Part 1: The Top 50) (Seeking Alpha)

Philip Morris International Inc. (NYSE: PM) hopes to market the IQOS cigarette as a less harmful alternative to cigarettes, but it

The Analyst

Height Securities' Stefanie Miller.

The Thesis

The Tobacco Products Scientific Advisory Committee rejected the claim that IQOS device can reduce the risk of tobacco-related diseases. Despite the negative news, the analyst said she expects that

Philip Morris' request is in-line with FDA Commissioner Scott Gottlieb's tobacco agenda. 

She doesn't find the TPSAC's vote surprising, because the questions they were asked Thursday were "specifically phrased." 

Center for Tobacco Products and Philip Morris can use the feedback they received Thursday to work together and make revisions to the company's application.

The hearing was focused only on whether the company will be allowed to make claims of reduced risk if IQOS gets approved for the U.S. distribution, said Miller. Whether it will be permitted to sell the product is going to be decided at a different hearing next month, the analyst said. It is important to understand that TPSAC has no regulatory jurisdiction and it only advises the CTP on various questions it may have, according to Height Securities. 

The Price Action

Philip Morris jumped 2.50 percent Friday after dropping 2.81 percent Thursday.

Related Links: 

Tobacco's Big Week 

What Were Once Vices Are Now Dividends: A Sinful New ETF 

Photo courtesy of Philip Morris. 

Latest Ratings for PM

Oct 2018CitigroupMaintainsBuyBuy
Oct 2018BernsteinInitiates Coverage OnOutperform
Sep 2018CitigroupMaintainsBuyBuy

View More Analyst Ratings for PM
View the Latest Analyst Ratings

Posted-In: Height Securities Stefanie Miller tobaccoAnalyst Color News FDA Analyst Ratings Best of Benzinga


Related Articles (PM)

View Comments and Join the Discussion!

Latest Ratings

XECImperial CapitalDowngrades35.0
SSTIImperial CapitalUpgrades49.0
AVDLoop CapitalUpgrades29.0
FCREYDeutsche BankUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Apple Q1 Earnings Preview: What Wall Street Is Saying Ahead Of The Report

Benzinga's Insider Buys Of The Week: BeiGene, Opko Health And More